This stock was pumped up with high dose of hypeium at the IPO.
We have to remember a large part of elective surgery all around the world was deferred or cancelled over the last 2 years as beds were reserved for COVID patients. Obviously OSX is dependent on elective surgery for it's core business so it's no surprise interest in this stock has been at all time lows.
The turn around will be the Q2 quarterly report, if revenues are back at $400-500k range it will indicate the previous growth trajectory is back on course, my bet is investors will flow back in.
There is allot happening in the background, the BoD are mostly Singaporean based and don't have a good handle on releasing news to the ASX and shareholders. They are more active on LinkedIn.
I am looking forward to the dental applications which are in clinical trails and sales momentum from the US starting to trickle in.
Don't give up just yet.
OSX Price at posting:
22.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)